Effects of High Potency Cannabis Products on Mental Health and Psychosocial Functioning

高效大麻产品对心理健康和心理社会功能的影响

• 批准号: 10618709
• 负责人: Christian J Hopfer
• 金额: $ 70.71万
• 依托单位: UNIVERSITY OF COLORADO DENVER
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-05-15 至 2028-03-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10618709
• 关键词: Accounting; Acute; Adolescence; Affect; Anxiety; Blood; Cannabinoids; Cannabis; Cannabis policy; Cannabis retail; Consumption; Controlled Study; Data; Dose; Drug usage; Education; Exhibits; Family; Flowers; Frequencies; Functional disorder; Genetic; Impulsivity; Individual; Individual Differences; Intoxication; Legal; Link; Literature; Marketing; Measures; Mental Depression; Mental Health; Methods; Neurocognitive; Outcome; Participant; Persons; Plasma; Prevalence; Psyche structure; Psychopathology; Reporting; Research; Risk; Risk Factors; Sales; Sampling; Symptoms; THC exposure; Testing; Time; Titrations; Twin Multiple Birth; Twin Studies; United States; Whole Blood; Work; design; low socioeconomic status; marijuana legalization; marijuana use; psychosocial; public health relevance; response; substance use

The rapidly changing landscape of cannabis policy in the United States is well known, but often overlooked is that legalization has made high-potency products more available. State-regulated cannabis markets offer access to cannabis products, such as concentrates with THC potencies (70-90%) that far exceed cannabis that has been sold on the black market over the last 20 years (4-12% THC potency). State reporting suggests that concentrates are commonly used and quickly rising in popularity, with increases in 2014-2019 sales (409%) far outpacing that of flower (80% increase) and edibles (234% increase). Recent data indicate that concentrate users exhibit higher plasma THC levels than flower users and a large body of research has demonstrated dose-response relationships between increasing cannabis consumption and poor mental health outcomes. Given the increasing prevalence of concentrate use, it is imperative to clearly understand how these increasingly popular, high-potency cannabis products affect mental health and psychosocial functioning. This project leverages an ongoing, longitudinal twin study, with participants assessed approximately every 5 years since adolescence. Thus, this project is a unique opportunity to rigorously test critical hypotheses about how high-potency concentrates affect psychopathology and psychosocial functioning. The Aims of this research are: Aim 1: Examine how the use of different cannabis products relates to cannabinoid exposure (e.g., THC). We will test whether the use of high-potency cannabis concentrates, compared to flower products, is associated with elevated cannabinoid exposure. We hypothesize that associations will not be explained by familial confounds (via co-twin comparisons) and individual differences (via repeated assessments). Alternatively, it is possible that concentrate users titrate to reach the same effect as flower users. Aim 2: Examine how the use of different cannabis products relates to mental health and psychosocial functioning. It is plausible that individuals vary in their propensity to use high-potency concentrates. Thus, we will examine how use of high-potency concentrates relate to mental health while accounting for familial and individual confounds, like genetics and prior substance use. We hypothesize that twins who uses more high- potency concentrates will tend to have greater levels of depression, anxiety, and impulsivity and psychosocial dysfunction compared to their co-twins who use flower or who use high-potency concentrates less frequently. Aim 3: Test whether different levels of cannabinoid exposure are associated with mental health and psychosocial outcomes. We will test how different levels of cannabinoid exposure (i.e., THC-COOH concentrations in whole blood) associate with depression, anxiety, and impulsivity as well as psychosocial functioning. That is, we will directly test the hypothesis that cannabinoid exposure is associated with mental health and psychosocial functioning. We hypothesize that higher levels of cannabinoid exposure will be associated with worse symptoms of mental health and psychosocial functioning.

美国众所周知，美国大麻政策的快速变化景观是 这种合法化使高位基因产品更加可用。国家监管的大麻市场优惠 使用大麻产品，例如具有THC效力的浓缩物（70-90％），远远超出了大麻 在过去的20年中，在黑市上已出售（4-12％的THC效力）。国家报告表明 浓缩物通常被使用，并且迅速越来越受欢迎，2014 - 2019年销售量增加（409％） 超过花朵的（增加80％）和食物（增加234％）。最近的数据表明浓缩物 用户表现出比花使用者更高的血浆THC水平，并且大量研究表明 剂量反应之间的关系增加了大麻消耗与精神健康不良结果。 鉴于浓缩物使用的患病率越来越高，必须清楚地了解这些 越来越受欢迎的高效大麻产品会影响心理健康和社会心理 功能。该项目利用持续的纵向双胞胎研究，并评估了参与者 自青春期以来大约每5年。因此，该项目是严格测试的独特机会 关于高功率浓缩物如何影响心理病理学和社会心理功能的关键假设。 这项研究的目的是： AIM 1：检查使用不同大麻产品与大麻素暴露之间的关系如何（例如， THC）。我们将测试与花产物相比，使用高功率大麻浓缩物是 与大麻素暴露升高有关。我们假设关联不会由 家族性混淆（通过联合比较）和个体差异（通过重复评估）。 另外，有可能将用户滴定液滴定到与花用户相同的效果。 目标2：检查使用不同大麻产品的使用与心理健康和心理社会的关系如何 功能。个人的使用倾向的倾向是合理的。因此，我们 将研究高功率浓缩物的使用与心理健康有关，同时会计家庭和 个人混淆，例如遗传学和先前的物质使用。我们假设使用更多高级的双胞胎 效力浓缩物将倾向于具有更大的抑郁，焦虑和冲动和心理社会的水平 与使用花朵或使用高功率的二线相比，功能障碍的频率较低。 目标3：测试不同水平的大麻素暴露是否与心理健康相关 社会心理结果。我们将测试不同水平的大麻素暴露（即THC-COOH） 全血的浓度）与抑郁，焦虑和冲动以及社会心理联系在一起 功能。也就是说，我们将直接检验以下假设，即大麻素暴露与心理有关 健康和社会心理功能。我们假设较高水平的大麻素暴露将是 与精神健康和社会心理功能的症状较差有关。